AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06432348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reformer pilates
Description: Before starting the exercises, a 5-minute warm-up session was performed. The reformer Pilates exercise program included movements such as the Footwork Series (Toes, Heels, Tendon Stretch, V Position), Supine Arm Series (Pull, Circle, Pull Head Up, Triceps Press), Short Box Series (Round, Flat Back, Twist), Short Box and Arm Series (Chest Fly, The Gift, Rhomboid, Biceps Curl, Rowing, Triceps), Long Box Series (Swan, Pulling Fly), Stomach Massage (Round, Twist), Knee Stretch (Round, Flat Back), Hip Work Series (Double Leg Press, Hamstring Pulls, Leg Circle, Frog), Elephant, and Side Stretch. Participants had two-minute rest intervals after the Supine Arm Series, Short Box, Arm Series, and Knee Stretch movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Reformer Pilates sessions and three team training days.
Study NCT06432348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mat Pilates
Description: Before the exercises, a 5-minute warm-up session was performed. The mat Pilates exercise program included movements such as Rol Up, One Leg Circle, Double Leg Straight Lower, One Leg Stretch, Criss Cross, Toe Top, Shoulder Bridge, Seated Tracking, Spine Twist, Up-Down Side Kick, Front-Back Side Kick, Circle Side Kick, Flight, Swan, Rest Position, Swimming, Push Up, Long Stretch, Cat Cow, Mermaid Stretch. The participants had two-minute rest breaks after the toe-top, spine twist, and circle side-kick movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Mat Pilates sessions and three team training days.
Study NCT05094375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol 600 mcg
Description: All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Study NCT05094375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Misoprostol 800 mcg
Description: All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Study NCT04678284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Homeless Medication Support (D-Homes)
Description: There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide brief diabetes education as needed.
Study NCT05958550 — intervention group
Intervention type: BEHAVIORAL
Intervention: The tympanic membrane temperature of patients was measured.
Description: After the patient entered the anesthesia recovery room ( PACU ) at the end of the operation, the ear canal was cleaned with cotton swabs by nurses trained in the use of ear temperature guns to avoid the impact of earwax. The patient was in a supine position, the patient 's head was fixed, the patient 's auricle was gently pulled back and up, the ear canal was straight, the ear temperature gun was put into the ear canal, the temperature of the patient 's left and right ears was measured uniformly, and the average value was taken as the final body temperature value. Thereafter, the same measurement was performed every 20 minutes until the patient left the resuscitation room.
Study NCT05812417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010
Description: DA-8010 5mg single dose administration
Study NCT05812417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-8010
Description: DA-8010 5mg single dose administration
Study NCT03210545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid betamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.
Study NCT05873764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg RV521/78 µCi [ 14C]-RV521.
Description: 200 mg RV521/78 µCi \[ 14C\]-RV521
Study NCT05029232 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MLPA for duchenne
Description: MLPA test for genetic testing to detect gene affection in DMD , and other tests for confirmation and follow up
Study NCT05106413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiCROS fitting
Description: Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible hearing device on the other ear.
Study NCT05106413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monaural fitting
Description: Each participant will be fitted with a hearing aid on the better hearing ear and no device on the poorer, unaidable ear.~Monaural hearing aid fitting acts as control intervention.
Study NCT05106413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unaided condition
Description: No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention.
Study NCT05106413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CROS baseline
Description: Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible device on the other ear. The difference to the BiCROS condition is the setup of the microphones in the CROS device and the compatible hearing device.~This test condition is only tested for speech intelligibility in diffuse noise and acts as control intervention.
Study NCT05027633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: given by IV
Study NCT05027633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: given by IV
Study NCT05027633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: given by IV
Study NCT05027633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: given by IV
Study NCT06375447 — intervention group
Intervention type: OTHER
Intervention: Routine clinical treatment
Description: Routine clinical treatment is based on the latest international guidelines for insomnia.
Study NCT05260814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric toothbrush with smart phone app
Description: Scaling and root planing, oral hygiene instructions with use of Sonicare Diamond Clean Smart®.
Study NCT06379243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVP/PKP
Description: PVP or PKP surgery in patients with osteoporotic vertebral compression fractures
Study NCT04847791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin
Description: Oral Administration of Bovine Lactoferrin -fixed dose 800 mg / day for 30 days
Study NCT04847791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
Study NCT05484362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-Glucose beverage as reference food
Description: Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
Study NCT05484362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15mg of Crocus Sativus as beverage
Description: Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
Study NCT05484362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30mg of Crocus Sativus as beverage
Description: Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
Study NCT04664400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symbolic conditioning
Description: Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) through symbolic conditioning (no actual heat stimuli, only pictures of thermometers)
Study NCT04664400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning
Description: Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from experience (with actual heat stimuli).
Study NCT04664400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions
Description: Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from verbal instructions.
Study NCT04664400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterfactual
Description: Thermal stimuli will be either the better outcome or the worse outcome out of two possible outcomes.
Study NCT06017271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CTPA (computed tomography pulmonary angiography)
Description: The CTPA diagnosis suggest or did not suggest pulmonary embolism.
Study NCT06474533 — intervention group
Intervention type: DRUG
Intervention: Fluorethyltyrosine (18-F)
Description: Given intravenously (IV)
Study NCT06474533 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography (PET)
Description: Undergo Imaging Procedure
Study NCT05319717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food with heat stabilized rice bran
Description: Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
Study NCT05319717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use therapeutic food (no rice bran)
Description: Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
Study NCT05189392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO
Description: after hip arthroplasty application of visible opsite plaster on the surgical wound
Study NCT05922254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active cycle of breathing technique
Description: The ACBT technique consists of three different breathing techniques: breathing control, thoracic expansion exercises and forced expiration technique. 1. Breathing Control 2. Thoracic Expansion Exercises: 3. Forced Expiration Technique:
Study NCT05922254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique
Description: The ACBT technique consists of three different breathing techniques: breathing control, thoracic expansion exercises and forced expiration technique. 1. Breathing Control 2. Thoracic Expansion Exercises: 3. Forced Expiration Technique:
Study NCT05922254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Description: Huffing or blowing the nose helped to get rid of any secretions in the upper airways. The therapist was placed close enough to hear the subject's breathing while sitting to the side and slightly behind the patient. Both the physiotherapist's hand and the subject's hands were put on the subject's abdomen to feel the activity of the abdominal muscles. The patient inhaled slowly through the nose while using their diaphragm and holding their breath for two to three seconds to allow collateral ventilation to bring air behind their secretions. Exhalation was done through the mouth. The palm of the therapist placed on the upper chest felt the vibration of the mucous. Their positions were disclosed by the vibrations' frequency.
Study NCT05988359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caries treatment with a dental turbine
Description: G1 (n=30) conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
Study NCT05988359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caries treatment with Er:YAG laser
Description: G2 (test, n=30) group, a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
Study NCT05664516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-1900 (Tonix Pharmaceuticals)
Description: oxytocin nasal spray
Study NCT05664516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal solution without oxytocin
Study NCT06452342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period
Study NCT06452342 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Tranexamic acid
Description: Routine clinical care without Tranexamic acid
Study NCT04889040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7496998
Description: 275 mg tablets
Study NCT04889040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablets
Study NCT06212882 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lower concentration and lower volume contrast agent group
Description: CT images using lower concentration and lower volume contrast material
Study NCT05170633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
Description: 70 random infant will receive the packed red blood cell transfusion with the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
Study NCT06417697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-101
Description: capsule formulation
Study NCT06417697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule formulation
Study NCT04958967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 240mg
Description: treated subjects will receive Furmonertinib 240mg/day
Study NCT05148962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R910
Description: Injection administered intramuscularly
Study NCT04958967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 160mg
Description: treated subjects will receive Furmonertinib 160mg/day
Study NCT04809506 — intervention group
Intervention type: BIOLOGICAL
Intervention: additional blood samples
Description: 2 additional blood samples (2 x 7ml) at every visit
Study NCT06055790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine (Axumin) PET/CT
Description: PET/CT protocol:~All patients will be instructed to fast for 4 hr. prior to the scan. CT imaging of the head will be performed using GE Discovery MI Digital PET/CT (Boston, Massachusetts) prior to the injection of 18F-fluciclovine. While the patient is in a supine position on the PET table, 5 mCi (185 MBq) of 18F-fluciclovine will be administrated intravenously, followed by a saline flush. At the time of the injection, a continuous dynamic PET images lasting 60 min will be performed using 3D-dynamic and list-mode acquisition: 2.0 mm slice thickness, number of frames(f) x time in seconds(s) and minutes(m) of: 4f x 15s, 4f x 30s, 6f x 2m, 5f x 3m, and 6f x 5m. PET images at 0-5 (flow), 15-25 (early), 25-35 (mid), 45-60 min (delayed) post-injection will be reconstructed using Qclear 500 and OSEM iterative reconstruction with TOF (VPFX): 8 iterations, 5 subsets, 440 image matrix, 4 mm Gaussian filter, TOF. \[24, 27\].
Study NCT04903730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER-901 Solution for Nebulization
Description: Part A: participants will be enrolled into 1 of up to 5 sequential cohorts (A1 to A5). Inhaled AER-901 doses of 5, 10, 20, 40, and 80mg are planned.~Part B: participants will be enrolled into 1 of up to 3 cohorts (B1 to B3).~Cohorts B2 and B3 will commence following Part D of the study and following SRC review of safety, tolerability, and PK data. A decision to dose with either a propylene glycol formulation or a sterile water formulation will be made by the SRC at the time of the review of the Part D data.~Part D has a three-part design (Treatment Periods 1 \& 2 separated by a Washout period) and will compare placebo to a single-dose of AER-901 (5 mg/mL QD) followed by two doses of AER-901.~Each cohort will consist of 8 participants (6 receiving AER 901 and 2 receiving placebo).
Study NCT04903730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.45% sterile saline for injection delivered via the FOX MOBILE device.
Study NCT05908253 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham neurofeedback
Description: Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
Study NCT05908253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonadaptive neurofeedback
Description: Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
Study NCT05908253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: adaptive neurofeedback
Description: Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
Study NCT05785377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Neostigmine
Description: 20 mL bupivacaine 0.25% plus 1 mL Neostigmine (500 mcg)
Study NCT05785377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 20 mL bupivacaine 0.25% plus 1 mL normal saline 0.9%
Study NCT04638634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL760
Description: An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin
Study NCT05180500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Q-Griffithsin
Description: Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.
Study NCT05180500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.
Study NCT06167200 — intervention group
Intervention type: OTHER
Intervention: No intervention, study is observational
Description: No intervention, study is observational
Study NCT03691480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple exsufflation
Description: simple exsufflation
Study NCT03691480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fuhrman catheter and ambulatory care
Description: Fuhrman catheter and ambulatory care